Vaccine injuries continue to accumulate in the Vaccine Adverse Event Reporting System and go unacknowledged, making any constructive discussion around risk impossible.
In order to find common ground, it is perhaps most appropriate to focus on published data from the vaccine trials themselves.
The CCCA presentation also resurrects a puzzling observation mentioned in a briefing document Pfizer submitted only to the FDA's Vaccine and Related Biologic Products Advisory Committee of the FDA, but nowhere else - including the widely cited summary of the trial reported in New England Journal of Medicine.
Table 12 from the corresponding summary to the FDA's VRBPAC indicated 3.1% of children were removed from the trial if they received the vaccine compared to 0.5% if they received the placebo.
It is true that the vaccine formulation requires steps prior to administration that are not required with the placebo, but why didn't these protocol deviations happen with the first dose as well? What happened to these vaccine recipients soon after they received their second dose?
This is precisely the most damning allegation by whistleblower Brook Jackson, formerly a regional director at Ventavia, one of several clinical research organizations conducting Pfizer's vaccine trials in 2020.
A thorough analysis of data from Pfizer's vaccine trials reveals more questions than answers.
Thursday, December 23, 2021
Pfizer "Vaccine" Clinical Trials Poorly Designed From the Start, Analysis Shows
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment